SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Stockholders Equity Over TimeExpanding
Percentile Rank100
3Y CAGR+69.6%
5Y CAGR+31.2%
Studio
Year-over-Year Change

Net worth of the company (assets minus liabilities)

3Y CAGR
+69.6%/yr
Annual compound
5Y CAGR
+31.2%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
3.9x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$151.49M+483.4%
2024$25.97M-54.7%
2023$57.30M+84.5%
2022$31.06M-19.4%
2021$38.55M-1.2%
2020$39.01M+1791.9%
2019$-2.31M-